BioFactura Funded $13 Million Contract Option for its Smallpox Biodefense Therapeutic
BioFactura Funded $13 Million Contract Option for its Smallpox Biodefense Therapeutic Share Article Confirms BARDA support of critical medical countermeasure development Dr. Darryl Sampey, President and CEO of BioFactura, stated, “Funding of our first option confirms the commitment of BARDA to support development of this important product. We look forward to continuing our close collaboration with BARDA as we move into the pathway to FDA approval." FREDERICK, Md. (PRWEB) February 19, 2021 BioFactura, Inc. today announced a con...
Source: prweb.com